EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Prognostic Value of Early Dynamic Changes in Skeletal Muscle Index for Unresectable Lung Squamous Cell Carcinoma: A Prospective Landmark Analysis

Xinjie Zhang, Xueni Liu, Chenglan Ye, Yixiao Fu, Jie Chen, Minhua Wu, Jianhui Huang, Yanru Xie

Thoracic Cancer · 2026-11 · 17 (21)

DOI: 10.1111/1759-7714.70396 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objectives To investigate the prognostic value of early dynamic skeletal muscle index (ΔSMI) changes in unresectable lung squamous cell carcinoma (LUSC) and explore associations with systemic inflammatory and nutritional markers. Materials and Methods This prospective study enrolled 76 patients with unresectable Stage III/IV LUSC. Routine computed tomography images at the fourth thoracic vertebra were analyzed before and 90 days posttreatment to quantify body composition changes. Progression‐free survival (PFS) was evaluated using landmark analysis to prevent immortal time bias. Multivariate Cox regression identified independent prognostic factors utilizing optimal cut‐offs from the maxstat algorithm. Results Only rapid skeletal muscle depletion (ΔSMI ≤ −5.0%) emerged as an independent predictor of adverse PFS (HR = 2.030, 95% CI: 1.132–3.642, p = 0.018), alongside clinical Stage IV ( p < 0.001); overall ΔBMI lacked prognostic significance. Patients with rapid muscle loss exhibited persistently elevated C‐reactive protein and steeper hemoglobin declines, reflecting an unresolved inflammatory and hypercatabolic state. Subgroup analyses confirmed ΔSMI's consistent prognostic value across age, sex, and stage (all P‐interaction > 0.05). Conclusion Early ΔSMI loss, not overall weight variation, independently predicts poor PFS in unresectable LUSC. Routine CT‐based body composition monitoring provides a critical window to identify high‐risk patients for interventions targeting the muscle‐inflammation axis. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2500104777.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →